Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283829 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00283829 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 30 participants.
The verdict
NCT00283829, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to test if interleukin-2, a drug that stimulates the immune system, can be used after chemotherapy to slow the progression of your disease. We also want to test what the best dose of interleukin-2 is that can be used safely at home. Interleukin-2, abbreviated as IL2, is a naturally produced growth hormone for the immune cells in our body. It stimulates the growth of the immune cells and enhances their ability to fight infections and cancers. In people with cancer, the immune cells are typically suppressed and became even more so after irradiation and chemotherapy treatment. By giving you more IL2 we hope to enhance the immune system so that it can fight the cancer better, control cancer growth and shrink the cancer.
Interventions
- DRUG docetaxel
- DRUG IL2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-09 |
| Est. Completion | 2006-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283829
The ClinicalTrials.gov registry entry for NCT00283829 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00283829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283829 about?
NCT00283829 is a clinical study titled "Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer". The purpose of this study is to test if interleukin-2, a drug that stimulates the immune system, can be used after chemotherapy to slow the progression of your disease. We also want to test what the best dose of interleukin-2 is that can be used safely at home. Interleukin-2, abbreviated as IL2, is...
What is the current status of trial NCT00283829?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-09. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00283829?
The interventions under investigation include: docetaxel (DRUG), IL2 (DRUG).
Who is sponsoring clinical trial NCT00283829?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.